hiv
remain
signific
global
burden
without
effect
vaccin
crucial
develop
microbicid
halt
initi
transmiss
viru
sever
microbicid
research
variou
level
success
amongst
broadli
neutralis
antibodi
peptid
lectin
promis
immedi
act
viru
proven
efficaci
vitro
vivo
protect
studi
purpos
develop
access
relev
popul
group
crucial
microbicid
produc
low
cost
promis
protein
peptid
candid
molecul
appear
current
product
system
overburden
expens
establish
maintain
recent
develop
vector
system
protein
express
coupl
downstream
protein
purif
technolog
plant
rapidli
gain
credibl
altern
product
system
evalu
advanc
made
host
vector
system
develop
plant
express
well
progress
made
express
hiv
neutralis
antibodi
peptid
lectin
use
plantbas
platform
recent
report
show
number
new
hiv
infect
declin
sinc
peak
diseas
almost
year
ago
unaid
howev
worldwid
million
peopl
still
live
diseas
unaid
furthermor
subsaharan
africa
heavili
hiv
affect
region
estim
popul
test
hiv
unaid
thu
global
still
exist
huge
reservoir
hivinfect
peopl
potenti
infect
million
despit
commend
research
effort
nearli
year
protect
hiv
vaccin
still
avail
thu
becom
crucial
develop
strategi
diseas
prevent
microbicid
would
effect
block
initi
transmiss
viru
women
compris
hiv
infect
popul
high
risk
candid
mani
case
unabl
protect
due
domest
violenc
cultur
social
habit
lack
educ
financi
secur
unaid
due
difficult
socioeconom
condit
success
microbicid
lend
formul
appli
topic
oral
order
women
selfmanag
use
moscicki
microbicid
develop
field
receiv
boost
progress
made
studi
demonstr
microbicid
gel
contain
tenofovir
revers
transcriptas
inhibitor
could
prevent
risk
hiv
infect
karim
et
al
antihiv
microbicid
candid
includ
surfact
vagin
milieu
protector
viral
entri
inhibitor
revers
transcriptas
inhibitor
agent
unknown
mode
action
cutler
justman
surfact
vagin
milieu
protector
first
gener
candid
microbicid
cutler
justman
broad
act
fail
produc
effect
hiv
inhibit
even
enhanc
infect
instanc
van
damm
et
al
first
surfact
test
clinic
trial
garg
et
al
although
advers
effect
report
preclin
phase
clinic
trial
genit
ulcer
irrit
inflamm
subsequ
higher
hiv
risk
report
phase
iii
trial
garg
et
al
moscicki
surfact
develop
microbicid
fade
risk
vagin
damag
inconclus
clinic
trial
vagin
milieu
protector
stabilis
low
mucos
ph
class
microbicid
acidform
amphora
instead
inc
dalla
tx
usa
buffergel
carbopol
reprotect
baltimor
md
usa
evalu
extens
display
good
contracept
properti
shown
well
toler
human
subject
whilst
vitro
antihiv
activ
report
acidform
subject
safeti
accept
preclin
studi
review
cutler
justman
http
wwwinsteadsciencescomamphorahtm
result
buffergel
fail
show
reduct
hiv
infect
compar
placebo
gel
studi
evalu
effect
reduct
hiv
incid
high
risk
studi
group
karim
et
al
thu
like
vagin
milieu
protector
effect
prevent
hiv
transmiss
singl
formul
probabl
use
combin
antivir
entiti
fact
carbopol
use
polym
base
formul
gel
applic
revers
transcriptas
inhibitor
tenofovir
garg
et
al
strategi
maintain
healthi
mucos
environ
includ
restor
microflora
popul
product
lactin
v
mucocept
osel
santa
clara
ca
usa
moscicki
entri
inhibitor
group
microbicid
interact
either
viral
host
cell
structur
prevent
attach
fusion
entri
first
type
entri
inhibitor
chemic
molecul
anion
polym
establish
interact
viru
base
surfac
charg
review
cutler
justman
compound
fail
show
signific
protect
clinic
trial
associ
unwant
side
effect
instanc
associ
enhanc
hiv
infect
risk
pironn
et
al
subsequ
microbicid
develop
focus
potent
specialis
molecul
revers
transcriptas
inhibitor
antagonist
viral
entri
inhibitor
revers
transcriptas
inhibitor
target
viral
enzym
campiani
et
al
cihlar
antagonist
compet
viru
host
cell
coreceptor
baba
schol
schol
whilst
entri
inhibitor
bind
viral
envelop
compon
prevent
entri
viru
cell
balzarini
boto
wlodaw
later
group
antibodi
peptid
lectin
repres
class
molecul
advanc
stage
develop
microbicid
avoid
repeat
past
failur
newli
research
microbicid
candid
molecul
current
undergo
strict
evalu
sever
preclin
test
studi
use
specialis
model
formul
buckheit
et
al
doncel
clark
mcgowan
rigour
necessari
preclin
test
clinic
trial
complex
expens
minc
mcgowan
largest
market
segment
hiv
prophylaxi
resid
resourc
limit
countri
ill
afford
develop
cost
cost
hurdl
crucial
microbicid
produc
minimum
upfront
capit
outlay
facilit
develop
test
ultim
avail
final
product
plant
emerg
cost
friendli
altern
product
system
varieti
pharmaceut
numer
therapeut
protein
produc
plant
system
gid
et
al
et
al
protein
base
microbicid
name
neutralis
antibodi
peptid
lectinslend
product
plant
de
muynck
et
al
matoba
et
al
okeef
et
al
sexton
et
al
although
microbicid
extens
studi
term
structur
mode
action
product
plant
host
express
system
audit
date
studi
evalu
progress
made
express
develop
peptid
antibodi
candid
microbicid
plant
past
two
decad
plant
extens
investig
altern
product
system
pharmaceut
protein
even
care
consider
exist
product
system
plant
provid
sever
attract
featur
equival
benefici
mett
et
al
twyman
et
al
twyman
et
al
like
mammalian
yeast
cell
plant
possess
cellular
machineri
enabl
perform
post
translat
modif
essenti
matur
sometim
function
protein
unlik
mammalian
ferment
system
plant
risk
contamin
human
pathogen
furthermor
compar
mammalian
yeast
system
plant
product
system
easili
scale
plant
either
propag
larg
number
design
land
plot
contain
greenhous
mainten
plant
soil
hydropon
cell
cultur
simpl
cheap
compar
complex
growth
media
requir
yeast
mammalian
cell
system
furthermor
plant
provid
huge
biomass
form
green
leafi
tissu
numer
seed
certain
crop
latter
provid
advantag
stabl
storag
longer
time
period
high
protein
content
exploit
recombin
protein
product
cunha
et
al
b
lau
sun
whilst
cost
downstream
process
remain
high
requir
purifi
protein
made
convent
system
burden
allevi
maximis
product
yield
utilis
innov
purif
strategi
improv
product
recoveri
paul
thu
plant
product
system
upfront
invest
requir
infrastructur
lower
potenti
lower
barrier
entri
player
especi
player
develop
countri
consid
time
effort
invest
twentyyear
rel
plant
made
pharmaceut
pmp
current
market
fay
gomord
main
reason
product
level
plant
often
low
commerci
viabl
regulatori
approv
pmp
perceiv
difficult
obtain
recombin
protein
initi
express
transgen
plant
stabl
nuclear
transform
use
agrobacteriummedi
deliveri
binari
vector
altern
method
biolist
introduct
dna
plant
cell
banta
montenegro
vianna
et
al
lengthi
labour
intens
process
mostli
gener
progeni
variabl
part
low
target
protein
accumul
level
express
multipl
compon
protein
antibodi
requir
numer
cross
screen
plant
breed
programm
transient
express
binari
vector
mainli
use
rapid
screen
valid
express
potenti
gene
gener
result
high
protein
accumul
gleba
et
al
whilst
viral
vector
use
produc
protein
plant
limit
insert
size
fidel
transcript
pogu
et
al
furthermor
system
spread
viru
sometim
result
loss
foreign
gene
insert
rais
concern
contain
howev
develop
arena
result
significantli
improv
stateoftheart
technolog
plant
base
protein
express
anoth
perceiv
limit
pmp
clinic
applic
variat
plant
glycan
structur
compar
human
gomord
et
al
shortcom
also
typic
system
yeast
insect
cell
mett
et
al
thu
far
clinic
signific
evid
plantspecif
glycan
inappropri
immunogen
human
van
der
veen
et
al
anoth
develop
done
lot
allay
fear
recent
fda
approv
plant
made
therapeut
gaucher
diseas
glucocerebrosidas
also
known
taligluceras
alfa
elelyso
produc
carrot
cell
proven
well
toler
perhap
even
efficaci
stablein
word
biobett
aviez
et
al
howev
pressur
remain
plant
product
system
deliv
therapeut
protein
humanis
glycan
profil
sever
advanc
express
vector
system
plant
host
address
limit
larg
extent
increas
protein
yield
second
gener
agrobacterium
binari
vector
incorpor
variou
element
enhanc
transcript
translat
veluthambi
et
al
improv
vector
use
conjunct
transient
infiltr
improv
protein
express
level
plant
instanc
transient
express
human
optimis
capsid
protein
gene
use
specialis
binari
ptra
vector
result
yield
gkg
fresh
leaf
weight
total
solubl
protein
maclean
et
al
signific
lower
level
obtain
protein
transgen
produc
tobacco
potato
result
protein
accumul
total
solubl
protein
respect
biemelt
et
al
develop
vector
system
seen
merg
viral
binari
vector
technolog
increas
yield
address
insert
size
restrict
retent
target
gene
contain
issu
icon
genet
gmbh
hall
germani
develop
deconstruct
viral
vector
system
initi
base
tobacco
mosaic
viru
tmv
target
gene
differ
viral
vector
compon
carri
sever
promodul
vector
marillonnet
et
al
system
viral
coat
protein
remov
elimin
system
spread
instead
agroinfiltr
provid
deliveri
modul
plant
cell
limit
replic
infiltr
area
cell
highlevel
express
facilit
rna
depend
rna
polymeras
sitespecif
recombinas
facilit
assembl
modul
dna
molecul
transcrib
splice
function
transcript
transcript
move
cytosol
translat
specifi
protein
altern
target
signal
incorpor
direct
protein
specifi
subcellular
compart
marillonnet
et
al
system
use
accumul
variou
protein
level
gkg
plant
materi
bendandi
et
al
one
shortcom
initi
icon
system
vector
inabl
coexpress
one
protein
spatial
locat
giritch
et
al
problemat
product
multicompon
protein
immunoglobulin
solut
came
coexpress
two
noncompet
monopartit
viral
genom
tmv
pvx
giritch
et
al
altern
viral
vector
deriv
bior
tripartit
viral
rna
genom
seem
compet
abl
cofunct
area
cowpea
mosaic
viru
cpmv
bipartit
viral
rna
genom
two
type
vector
system
develop
fulllength
system
wild
type
wt
code
sequenc
protein
interest
fuse
cterminu
polypeptid
cotransl
releas
via
mediat
cleavag
replic
facilit
coexpress
fulllength
version
allow
local
coexpress
two
differ
protein
howev
segreg
coexpress
protein
occur
system
movement
delet
cpmv
version
hypertranslat
ht
develop
lack
abil
system
spread
thu
abl
coexpress
one
protein
without
occurr
segreg
moreov
delet
cpmv
system
obtain
higher
express
level
fulllength
version
sainsburi
et
al
use
system
protein
express
level
exceed
gkg
protein
sever
pharmaceut
import
molecul
express
plant
use
vector
base
ssdna
geminiviru
bean
yellow
dwarf
viru
beydv
chen
et
al
huang
et
al
regnard
et
al
independ
develop
vector
system
base
dna
genom
viru
beydv
system
requir
two
viral
compon
coexpress
heteromer
protein
long
intergen
region
lir
short
intergen
region
sir
control
sequenc
singl
altern
splice
gene
replicationassoci
protein
reprepa
system
noncompet
coexpress
achiev
either
two
replicon
encod
differ
protein
singl
replicon
contain
differ
protein
nicotiana
benthamiana
transient
express
level
beydv
vector
egfp
compar
level
obtain
use
binari
ptra
agrobacterium
tumefacien
vector
regnard
et
al
furthermor
express
beydv
result
accumul
level
gkg
monoclon
antibodi
ebola
viru
mab
huang
et
al
anticip
system
abl
simultan
produc
mani
four
differ
protein
subunit
sever
geminivirus
also
multicompon
ssdna
nanovirus
investig
potenti
express
vector
develop
could
greatli
expand
rang
plant
speci
use
transient
product
recombin
protein
rybicki
martin
eukaryot
nglycan
biosynthesi
pathway
conserv
endoplasm
reticulum
er
kukuruzinska
lennon
variat
speci
occur
modif
glycan
structur
process
step
protein
exit
er
plant
variat
depend
protein
plant
speci
plant
organ
use
express
unless
plant
glycosyl
form
therapeut
protein
attract
case
carrot
cell
produc
glucocerebrosidas
shaaltiel
et
al
consid
ideal
plant
abl
produc
therapeut
protein
mammallik
glycan
glycan
structur
critic
protein
function
recombin
protein
without
glycan
structur
desir
rodriguez
et
al
therapeut
protein
produc
aglycosyl
form
feasibl
protein
need
stimul
inflammatori
respons
case
recombinantli
produc
antibodi
requir
effector
function
sinc
glycan
structur
often
crucial
biolog
function
protein
jefferi
current
gel
formul
hiv
neutralis
antibodi
peptid
lectin
tsai
et
al
suggest
microbicid
like
appli
topic
expos
mucos
surfac
limit
interact
immun
system
thu
caus
inflamm
thu
product
microbicid
plant
natur
glycan
structur
microbicid
might
import
yield
obtain
anoth
mean
produc
protein
close
resembl
humanis
glycan
profil
restrict
recombin
protein
er
use
kdel
hdel
sekdel
er
retent
signal
ko
et
al
triguero
et
al
regulatori
purpos
gener
regard
safer
produc
nativ
version
protein
howev
case
er
retent
signal
regulatori
approv
might
less
stringent
see
sequenc
also
found
mammalian
protein
note
protalix
carrot
cell
produc
glucocerebrosidas
receiv
fda
approv
produc
storag
vacuol
target
signal
shaaltiel
et
al
anoth
argument
er
retent
product
protein
er
retent
need
increas
accumul
level
bortesi
et
al
yang
et
al
hand
er
retent
result
degrad
protein
low
stabil
reduc
half
life
therapeut
vivo
ko
et
al
loo
et
al
studi
also
shown
er
retent
recombinantli
produc
protein
alway
success
achiev
lead
protein
leak
er
process
contain
complex
immunogen
plant
glycan
floss
et
al
loo
et
al
rademach
et
al
subsequ
improv
plant
host
develop
aim
humanis
glycan
pattern
recombin
protein
plant
arabidopsi
tobacco
moss
gener
plantspecif
glycosyl
gene
knock
koprivova
et
al
et
al
strasser
et
al
mutant
plant
specif
residu
replac
complex
nacetylglucosamin
gngn
structur
glycan
improv
made
coexpress
mammal
like
glycosyl
sialyl
enzym
galt
nacetylglucosaminyltransferas
iii
gntiii
core
udpnacetylglucosamin
kinas
gne
nacetylneuramin
acid
phosphatas
synthas
nan
cmpnacetylneuramin
acid
synthetas
cma
cmpnacetylneuramin
acid
transport
st
plant
glycosyl
knockout
mutant
castilho
et
al
castilho
et
al
strasser
et
al
result
protein
lack
plantspecif
glycan
also
contain
human
glycan
structur
neutralis
antibodi
play
import
role
develop
vaccin
passiv
immunis
viral
entri
inhibitor
reina
et
al
direct
viral
envelop
protein
interfer
viral
dock
fusion
thu
inhibit
infect
viru
also
potenti
facilit
viral
clearanc
via
fc
relat
effector
function
sever
neutralis
antibodi
isol
hiv
infect
individu
simek
et
al
walker
et
al
wu
et
al
novel
broad
act
neutralis
antibodi
isol
display
larger
breadth
potenc
wellknown
neutralis
antibodi
wu
et
al
howev
four
wellknown
neutralis
antibodi
name
well
research
term
structur
interact
viru
protect
anim
model
safeti
clinic
trial
produc
variou
plant
platform
antibodi
fare
well
protect
macaqu
system
vagin
simianhuman
immunodefici
viru
shiv
challeng
well
toler
human
subject
armbrust
et
al
armbrust
et
al
hessel
et
al
mascola
et
al
mascola
et
al
parren
et
al
furthermor
passiv
administr
neutralis
monoclon
antibodi
mab
reduc
viral
rebound
establish
hiv
infect
trkola
et
al
three
neutralis
monoclon
antibodi
mab
assess
gel
formul
microbicid
phase
clinic
trial
safeti
pharmacokinet
effect
far
vaccin
attempt
antibodi
epitop
fail
produc
equival
neutralis
antibodi
human
et
al
lenz
et
al
mcgaughey
et
al
thu
like
therefor
antibodi
administ
passiv
larg
product
quantiti
requir
mammalian
cell
current
use
fdaapprov
therapeut
antibodi
product
given
capac
tradit
fermentor
system
meet
demand
plant
employ
altern
manufactur
platform
sever
antibodi
success
produc
plant
platform
de
muynck
et
al
apart
yield
glycan
composit
efficaci
import
criteria
plant
made
manufactur
antibodi
therefor
evalu
progress
plant
product
neutralis
antibodi
light
criteria
tabl
summaris
express
four
antibodi
plant
system
report
neutralis
b
clade
viru
entri
recognit
rich
epitop
exterior
face
protein
binley
et
al
scanlan
et
al
monoclon
antibodi
mab
activ
complement
system
display
antibodi
depend
cellular
cytotox
adcc
viru
infect
cell
trkola
et
al
passiv
infus
combin
neutralis
antibodi
includ
protect
macaqu
vagin
intraven
challeng
shiv
baba
et
al
mascola
et
al
passiv
infus
well
toler
human
subject
phasei
clinic
trial
armbrust
et
al
clinic
trial
produc
transgen
tobacco
commenc
paul
mab
uniqu
structur
natur
form
singl
fab
region
via
domain
swap
variabl
region
light
chain
v
l
heavi
chain
v
h
constant
region
light
chain
c
l
heavi
chain
c
h
respect
calares
et
al
west
et
al
dimer
shown
time
effici
monom
neutralis
sever
strain
vitro
west
et
al
vivo
assay
luo
et
al
product
activ
pursu
maiz
arabidopsi
tobacco
mab
produc
seed
endosperm
two
differ
maiz
line
control
rice
glutelin
promot
antibodi
produc
hiii
maiz
endoplasm
reticulum
er
retent
signal
elit
maiz
line
secret
form
ramessar
et
al
er
retain
antibodi
accumul
mention
fusion
abl
bind
viru
neutralis
assay
sexton
et
al
gener
gener
whilst
secret
form
reach
identif
glycan
structur
show
major
er
retain
antibodi
contain
oligomannos
type
glycan
omt
howev
immunoglobulin
contain
glycan
vacuolar
type
indic
er
retent
complet
success
differ
glycoform
detect
secret
major
singl
nacetylglucosamin
glcnac
residu
rest
contain
complex
type
fucos
xylos
glycan
small
number
also
contain
omt
type
glycan
efficaci
maiz
produc
antibodi
compar
chines
hamster
ovari
cell
cho
produc
deriv
er
retain
secret
similar
antigen
bind
abil
cho
produc
howev
hiv
neutralis
assay
er
retain
secret
form
four
threefold
effect
cho
produc
equival
respect
increas
potenc
attribut
dimeris
aggreg
antibodi
arabidopsi
express
leav
et
al
seed
loo
et
al
knockout
line
lack
abil
gener
immunogen
plantspecif
glycan
strasser
et
al
leav
express
driven
camv
promot
without
er
retent
signal
antibodi
level
vari
tsp
wildtyp
wt
line
et
al
glycan
antibodi
produc
line
mainli
termin
nacetylglucosamin
gn
residu
lack
plantspecif
residu
small
popul
antibodi
molecul
produc
contain
omt
residu
indic
process
antibodi
incomplet
notabl
bind
capac
produc
antibodi
similar
cho
produc
seed
express
arabidopsi
express
driven
promot
loo
et
al
antibodi
express
without
er
retent
signal
signific
differ
accumul
level
secret
er
retain
antibodi
express
level
peak
around
nglycan
profil
purifi
antibodi
reveal
secret
antibodi
wild
type
line
contain
complex
nglycan
contain
nacetylglucosaminexylosefucos
gngnxf
residu
whilst
produc
mutant
line
contain
homogen
nglycan
structur
consist
nacetylglucosamin
gngn
major
er
retriev
antibodi
wild
type
line
contain
oligomannosid
nglycan
small
amount
antibodi
carri
gngnxf
efficaci
seed
produc
hiv
neutralis
assay
slightli
inferior
cho
deriv
n
benthamiana
leav
transient
express
use
full
length
delet
ht
version
cpmv
vector
sainsburi
et
al
antibodi
express
system
without
er
retent
signal
overal
higher
antibodi
accumul
obtain
use
delet
cpmv
vector
er
retent
signal
level
mgkg
report
glycan
analysi
antibodi
show
er
retain
form
consist
mainli
oligomannos
type
structur
omt
contain
complex
glycan
secret
antibodi
contain
complex
gngnxf
nacetylglucosaminemannosexylosefucos
gnmxf
omt
also
present
vitro
evalu
bind
abil
neutralis
efficaci
n
benthamiana
produc
antibodi
show
equal
mammalian
cell
deriv
humanis
glycan
structur
strasser
et
al
produc
n
benthamiana
galt
mutant
line
n
benthamiana
line
produc
plantspecif
xylos
fucos
glycan
produc
partial
humanis
glycan
via
activ
highli
activ
human
deriv
although
mention
made
accumul
level
antibodi
produc
system
fulli
galactosyl
effect
neutralis
cho
produc
version
mab
display
broader
neutralis
activ
inhibit
hiv
isol
clade
b
e
binley
et
al
dock
onto
core
epitop
eldkwa
lipid
embed
membran
proxim
exterior
region
mper
potenti
interfer
fusion
step
viru
binley
et
al
de
rosni
et
al
franquelim
et
al
muster
et
al
combin
antibodi
includ
display
abil
protect
intraven
vagin
oral
challeng
shiv
macaqu
baba
et
al
hessel
et
al
mascola
et
al
mascola
et
al
furthermor
passiv
administr
antibodi
seem
caus
immun
respons
advers
effect
hiv
infect
human
particip
armbrust
et
al
product
explor
nicotiana
speci
heavi
chain
hc
light
chain
lc
express
sekdel
retent
sequenc
tandem
control
camv
promot
nicotiana
tabacum
l
cv
bright
yellow
cell
cultur
sack
et
al
accumul
reach
maximum
mgkg
fresh
weight
enrich
proteina
purif
mgkg
wet
cell
weight
degrad
product
observ
follow
purif
howev
minor
impur
detect
nglycan
expect
omt
confirm
analys
fc
region
bind
cho
produc
equival
howev
antigen
bind
capac
cho
produc
slightli
superior
plant
deriv
hiv
neutralis
studi
produc
antibodi
threefold
less
effici
cho
produc
counterpart
lower
potenc
attribut
either
presenc
impur
ad
sekdel
motif
differ
glycan
structur
could
interf
antibodi
access
epitop
enhanc
accumul
tobacco
antibodi
express
er
retain
elastinlik
polypeptid
elp
fusion
floss
et
al
elp
peptid
use
facilit
accumul
protein
green
leaf
tissu
patel
et
al
four
transgen
hc
unfus
hcelp
fuse
lc
unfus
lcelp
fuse
introduc
n
tabacum
cv
samsun
nn
plant
subsequ
cross
result
combin
neither
gene
carri
fusion
hc
lc
carri
elp
fusion
either
hc
lc
fuse
elp
prior
cross
transgen
line
observ
presenc
elp
increas
accumul
chain
lc
accumul
higher
level
hc
cross
line
lcelp
fusion
facilit
higher
accumul
unfus
hc
well
accumul
total
solubl
protein
tsp
level
reach
lcelphc
hcelplc
hcelplcelp
hclc
elp
fusion
eas
purif
process
plantproduc
antibodi
interfer
assembl
antibodi
glycan
plantproduc
mainli
oligomannos
type
omt
lesser
amount
complex
glycan
consist
nacetylglucosamin
gngn
nacetylglucosaminexylos
gngnx
galactosylnacetylglucosaminexylos
agnx
nacetylglucosaminemannosexylos
gnmx
nacetylglucosaminexylosefucos
gngnxf
moieti
variant
similar
cho
produc
antigen
bind
capac
mab
one
broadli
neutralis
antibodi
activ
sever
viral
isol
differ
clade
includ
clade
c
preval
clade
heavili
affect
subsaharan
africa
region
binley
et
al
walker
et
al
abl
neutralis
key
hiv
subtyp
walker
et
al
wu
et
al
although
potent
use
differ
mode
action
viru
interact
envelop
way
resembl
interact
li
et
al
epitop
interact
also
somewhat
complex
antibodi
recognis
linear
epitop
adjac
epitop
membran
proxim
exterior
region
mper
interact
lipid
cell
membran
franquelim
et
al
zwick
et
al
whether
lipid
bind
involv
broadli
neutralis
abil
still
debat
scherer
et
al
xu
et
al
thu
antibodi
use
combin
sever
hiv
isol
phase
clinic
trial
demonstr
safe
administ
hiv
infect
particip
alon
combin
armbrust
et
al
administ
intraven
rhesu
macaqu
protect
mucos
challeng
shiv
hessel
et
al
mab
express
via
nuclear
transform
n
benthamiana
strasser
et
al
produc
wild
type
wt
glycoengin
mutant
line
galt
line
produc
alter
version
human
glycan
wt
produc
contain
nacetylglucosaminexylosefucos
gngnxf
nacetylglucosamin
gngn
xtfx
mutant
galactosyl
aa
glycan
xtfx
galt
line
later
mab
form
potent
plant
made
form
effici
cho
produc
deriv
neutralis
assay
possibl
galactosyl
glycan
enhanc
stabil
halflif
function
antibodi
mab
effect
hiv
neutralis
across
differ
clade
differ
geograph
locat
binley
et
al
unlik
neutralis
antibodi
restrict
certain
conform
viru
vitro
studi
show
bind
differ
conform
envelop
eggink
et
al
zhou
et
al
antibodi
shown
protect
macaqu
vagin
challeng
shiv
administ
system
topic
parren
et
al
veazi
et
al
mab
express
milk
femal
mice
display
hiv
neutralis
abil
cho
cell
deriv
antibodi
yu
et
al
combin
potent
inhibit
hiv
infect
cervic
tissu
hu
et
al
importantli
combin
administ
alon
mab
abl
stay
associ
viru
leav
mucos
environ
migrat
cell
prevent
subsequ
infect
target
lymphocyt
hu
et
al
van
montfort
et
al
neutralis
antibodi
studi
display
properti
sexton
et
al
produc
cyanovirin
fusion
n
tabacum
cvn
cyanobacterium
lectin
display
potent
antihiv
activ
plant
gener
express
hc
lc
fusion
cvn
fuse
hc
subsequ
cross
perform
gener
progeni
express
unfus
well
fusion
author
demonstr
modul
fusion
molecul
function
fusion
molecul
potent
cvn
alon
hiv
neutralis
assay
glycan
profil
plant
made
protein
present
lectin
protein
nonimmun
origin
select
bind
carbohydr
moieti
goldstein
hay
protein
isol
life
form
includ
bacteria
virus
alga
mushroom
nematod
plant
base
plant
lectin
inform
distinct
famili
alreadi
describ
van
damm
et
al
lectin
use
sever
applic
includ
pest
resist
crop
plant
peuman
van
damm
therapeut
agent
cancer
treatment
liu
et
al
liu
et
al
antivir
microbicid
candid
francoi
balzarini
hiv
envelop
heavili
popul
mainli
high
mannos
type
glycan
door
et
al
geyer
et
al
come
surpris
major
antihiv
lectin
show
affin
mannos
moieti
boto
wlodaw
interact
glycan
residu
viral
envelop
prevent
attach
fusion
mani
lectin
broad
rang
activ
differ
viral
clade
variou
serotyp
coreceptor
depend
furthermor
display
potenti
inhibit
viral
captur
dissemin
dcsign
bear
host
cell
balzarini
et
al
nabatov
et
al
antihiv
peptid
lectin
fall
differ
famili
differ
mode
interact
mannos
glycan
furthermor
variat
occur
quaternari
structur
efficaci
level
toward
hiv
immun
stimulatori
effect
human
cell
barr
et
al
wlodaw
antihiv
lectin
review
extens
regard
structur
mode
bind
balzarini
francoi
balzarini
wlodaw
major
lectin
remark
stabl
across
broad
ph
rang
high
temperatur
allow
manipul
express
purif
formul
applic
microbicid
repres
rich
sourc
protein
develop
antihiv
microbicid
first
group
antihiv
lectin
origin
isol
plant
van
damm
et
al
thereaft
numer
other
isol
organ
includ
prokaryot
alga
bacteria
fungi
nematod
bulgheresi
et
al
chiba
et
al
inokoshi
et
al
mori
et
al
zhao
et
al
recombin
express
lectin
plant
appli
extent
introduc
pest
resist
valuabl
crop
promot
rhizospher
symbiot
associ
zemek
sreevidya
et
al
wang
et
al
plant
lectin
show
antihiv
activ
isol
directli
natur
sourc
case
galathu
nivalu
agglutinin
gna
bulb
snowdrop
g
nivalu
contain
reason
high
level
lectin
van
damm
et
al
hand
hiv
inhibit
lectin
prokaryot
plant
produc
low
quantiti
thu
feasibl
direct
isol
sourc
kosht
et
al
lectin
isol
cyanobacteria
red
alga
funga
display
gener
higher
potenc
plant
lectin
extens
research
topic
antihiv
microbicid
sinc
protein
seem
occur
low
quantiti
nativ
host
recombin
product
altern
system
plant
explor
lectin
occur
natur
plant
seem
product
recombin
lectin
sourc
problemat
howev
come
light
plant
produc
two
type
lectin
classic
nucleocytoplasm
lannoo
van
damm
van
damm
et
al
classic
lectin
resid
storag
organel
whilst
nucleocytoplasm
lectin
occur
mainli
cytoplasm
gener
classic
lectin
synthesis
signal
peptid
produc
abund
serv
defenc
storag
purpos
plant
nucleocytoplasm
lectin
produc
without
signal
peptid
small
quantiti
thought
play
role
regulatori
process
plant
cell
lannoo
van
damm
thu
evid
plant
cell
clear
distinct
signal
abund
differ
lectin
differ
role
thu
heterolog
product
lectin
plant
could
effect
viabil
plant
cell
nativ
role
mani
hiv
neutralis
lectin
resolv
although
major
mainli
bind
mannos
residu
viral
envelop
one
rule
possibl
ligand
may
exist
plant
cell
environ
may
affect
express
accumul
recoveri
plant
matrix
thu
subcellular
target
may
play
import
role
resolut
optim
compart
high
yield
lectin
accumul
detriment
plant
cell
heterolog
express
progress
made
heterolog
express
antihiv
lectin
plant
briefli
review
tabl
highlight
major
find
cyanovirin
cvn
kda
protein
isol
bluegreen
alga
nostoc
ellipsosporum
ec
valu
nm
cvn
inhibit
vitro
fusion
target
cell
well
subsequ
viral
spread
viru
infect
uninfect
cell
display
antivir
activ
primari
laboratori
modifi
hiv
strain
sever
clade
includ
dual
tropic
virus
furthermor
cvn
inhibit
bind
coreceptor
depend
strain
dey
et
al
mori
boyd
antivir
activ
cvn
hepat
c
hell
et
al
ebola
barriento
et
al
smee
et
al
shiv
measl
herp
viru
dey
et
al
also
report
cvn
low
homolog
known
protein
sequenc
contain
sequenc
motif
typic
cvn
type
lectin
famili
gustafson
et
al
percudani
et
al
van
damm
et
al
solut
cvn
exist
monom
dimer
depend
ph
temperatur
condit
barriento
gronenborn
barriento
et
al
cvn
interact
termin
mannos
residu
oligomannos
glycan
structur
bewley
oteroquintero
shenoy
et
al
monom
contain
two
carbohydr
bind
domain
differ
affin
diand
trimannos
respect
bewley
oteroquintero
although
antihiv
activ
report
monomer
dimer
form
appear
potenc
cvn
depend
format
multisit
interact
glycan
residu
rather
affin
presenc
bind
domain
barriento
et
al
fromm
et
al
kelley
et
al
vitro
test
host
cell
cvn
display
littl
loss
cell
viabil
result
host
cell
exposur
cvn
furthermor
vivo
studi
gelformul
cvn
caus
advers
effect
test
anim
tsai
et
al
howev
extens
test
show
cvn
induc
product
chemokin
cytokin
stimul
cell
prolifer
husken
et
al
cytotox
howev
link
carbohydratebind
properti
thu
develop
mutat
pegyl
zapp
et
al
could
potenti
reduc
cytotox
cvn
lectin
might
still
consid
potenti
microbicid
cvn
use
groundbreak
microbicid
develop
work
pave
way
futur
develop
lectin
viabl
microbicid
molecul
display
potenti
lectin
use
gel
formul
microbicid
protect
vagin
rectal
challeng
hiv
tsai
et
al
cvn
recombinantli
produc
commerci
bacteria
streptococci
gordonni
giomarelli
et
al
pozzi
et
al
lactobacillu
jensinii
liu
et
al
cvn
display
surfac
gordonni
abl
captur
hiv
virion
whilst
secret
bacteria
could
bind
recombin
l
jensinii
abl
colonis
vagina
mice
secret
full
length
cvn
l
jensinii
produc
cvn
abl
inhibit
hiv
vitro
nanomolar
concentr
sever
fusion
cvn
explor
differ
applic
mind
exampl
form
high
potenc
chimaera
cvn
fuse
broadli
neutralis
antibodi
sexton
et
al
linear
peptid
mcfadden
et
al
partner
fusion
activ
new
chimaera
display
similar
stabil
higher
antivir
activ
cvn
also
fuse
pseudomona
exotoxin
chimer
protein
potent
elimin
hiv
infect
cell
express
surfac
recombin
express
cvn
altern
system
recent
review
xiong
et
al
brief
initi
product
purif
escherichia
coli
optim
result
low
level
cvn
accumul
optimis
result
high
accumul
level
consist
heterogen
cvn
popul
intact
truncat
signal
peptid
contain
cvn
form
chaperon
fusion
cvn
result
homogen
cvn
accumul
mgl
express
cvn
also
pursu
yeast
result
low
yield
nonfunct
protein
sexton
et
al
show
feasibl
produc
cvn
tobacco
plant
well
hydropon
cultur
cvn
gene
transform
n
tabacum
express
camv
constitut
promot
er
target
signal
peptid
cvn
accumul
ngmg
fresh
leaf
weight
tsp
hydropon
cultur
deriv
transgen
plant
secret
cvn
crude
cvn
extract
tobacco
abl
inhibit
hiv
infect
tzmbl
cell
compar
purifi
e
coli
deriv
cvn
cvn
also
produc
tobacco
fusion
monoclon
antibodi
sexton
et
al
fusion
accumul
activ
cvn
alon
griffithsin
grft
isol
red
alga
griffithsia
mori
et
al
amino
acid
sequenc
contain
unknown
amino
acid
posit
code
kda
protein
sequenc
unrel
known
protein
fold
state
monom
display
motif
found
lectin
jacalin
whilst
dimer
form
uniqu
domain
swop
two
grft
molecul
typic
found
lectin
famili
grft
display
broad
activ
corona
virus
hiv
okeef
et
al
grft
shown
antivir
activ
hiv
clade
b
c
preval
subsaharan
africa
india
west
activ
clinic
laboratori
adapt
tropic
hivisol
inhibit
orient
strain
prokaryot
antihiv
lectin
grft
thu
far
one
potent
promis
lectin
microbicid
develop
ec
valu
low
nm
mori
et
al
potenc
lectin
attribut
remark
dimer
structur
contain
six
mannos
bind
site
like
space
optim
interact
subsequ
cross
link
glycan
coat
protein
moulaei
et
al
success
topic
appli
microbicid
must
ultim
abl
function
mucos
environ
given
infect
rate
hiv
quit
rapid
microbicid
remain
stabl
efficaci
neutralis
hiv
immedi
contact
presenc
furthermor
compromis
tissu
viabil
initi
inflammatori
respons
light
criteria
preclin
test
show
grft
good
microbicid
candid
grft
virucid
upon
contact
viru
remain
stabl
sever
hour
prior
applic
emau
et
al
grft
stabl
function
cervic
lavag
fluid
wide
ph
rang
furthermor
grft
cytotox
human
primat
cell
line
initi
inflammatori
respons
caus
advers
effect
rabbit
vagin
irrit
model
emau
et
al
okeef
et
al
like
effect
antihiv
therapeut
consist
one
microbicid
limit
risk
viral
resist
thu
import
candid
microbicid
compat
microbicid
without
compromis
efficaci
safeti
compon
molecul
grft
test
combin
tenofovir
nucleotid
revers
transcriptas
inhibitor
maraviroc
hiv
coreceptor
inhibitor
enfuvirtid
fusion
inhibitor
cald
b
c
viru
isol
evalu
possibl
synergist
effect
lectin
combin
microbicid
et
al
grft
combin
microbicid
potenc
combin
higher
individu
molecul
recombin
product
grft
initi
pursu
e
coli
although
lectin
accumul
mgl
irrevers
lost
inclus
bodi
whilst
express
grft
e
coli
illustr
feasibl
altern
product
system
function
grft
remain
expens
product
platform
high
optimis
mainten
demand
okeef
et
al
use
tmv
base
vector
system
transient
product
grft
cytosol
n
benthamiana
leav
grft
accumul
gkg
fresh
weight
allow
purif
g
grft
kg
process
leaf
materi
bind
potenti
efficaci
plant
made
grft
similar
e
coli
produc
nativ
grft
respect
demonstr
potenti
plant
express
approach
viabl
altern
product
lectin
use
candid
microbicid
actinohivin
ah
lectin
isol
actinomycet
longispora
abida
report
ic
valu
nm
chiba
et
al
ah
harbour
lot
potenti
develop
antihiv
microbicid
lectin
inhibit
tropic
hiv
strain
particularli
potent
c
clade
virus
chiba
et
al
matoba
et
al
furthermor
ah
exhibit
impress
safeti
profil
lectin
caus
prolifer
mitogen
stimul
host
cell
hoorelbek
et
al
unlik
prokaryot
lectin
ah
bind
cluster
high
mannos
type
glycan
instead
singl
moieti
chiba
et
al
tanaka
et
al
thu
possibl
cluster
bind
ah
confer
specif
toward
glycan
type
typic
hiv
envelop
link
low
mitogen
effect
matoba
et
al
investig
plant
base
product
system
ah
nativ
gene
chiba
et
al
express
use
icon
vector
system
express
level
mgkg
obtain
small
ubiquitinlik
modifi
sumo
fuse
nterminu
ah
protein
level
accumul
mgkg
apoplast
davi
plantproduc
ah
abl
inhibit
hiv
mediat
syncytium
format
burden
continu
hiv
pandem
togeth
lack
effect
vaccin
spur
develop
sever
microbicid
candid
molecul
curb
hiv
transmiss
neutralis
antibodi
peptid
lectin
shown
encourag
potenc
protect
viru
vivo
vitro
studi
plant
present
viabl
option
cost
effect
product
protein
base
candid
microbicid
review
progress
made
product
hiv
neutralis
antibodi
peptid
lectin
plant
system
far
four
hiv
neutralis
success
made
plant
express
level
transgen
plant
leav
seed
plant
cell
cultur
rel
low
compar
obtain
transient
express
technolog
instanc
transient
infiltr
use
new
gener
viral
vector
technolog
delet
cpmv
vector
result
accumul
mgkg
express
target
product
variou
subcellular
locat
gener
use
optimis
recombin
protein
yield
case
antibodi
aspect
express
also
influenc
glycan
structur
molecul
also
depend
plant
organ
subcellular
target
influenc
overal
yield
efficaci
plant
made
antibodi
er
retent
arabidopsi
seed
show
signific
differ
express
level
result
almost
twofold
lower
level
maiz
seed
contrast
maiz
seed
er
retent
tobacco
leav
improv
yield
furthermor
er
retent
seem
entir
optim
leav
small
fraction
immunoglobulin
contain
immunogen
plant
glycan
separ
downstream
process
add
product
cost
promis
solut
lie
use
modifi
host
system
incap
produc
plant
glycan
instead
add
human
type
glycan
secret
protein
produc
modifi
n
benthamiana
plant
result
antibodi
contain
human
like
galactosyl
glycan
structur
furthermor
galactosyl
antibodi
efficaci
cho
produc
equival
mention
made
accumul
level
antibodi
mutant
plant
abil
express
mab
product
human
glycan
profil
repres
signific
step
toward
product
plant
fulli
function
protein
like
well
toler
difficult
say
factor
influenc
efficaci
plant
made
immunoglobulin
whilst
plant
made
antibodi
activ
cho
counterpart
other
less
effect
other
yet
fourfold
activ
impur
recov
product
glycan
structur
might
play
role
decreas
activ
whilst
aggreg
humanlik
glycan
structur
appear
improv
activ
case
mab
antibodi
produc
maiz
modifi
tobacco
furthermor
fusion
antihiv
agent
also
show
increas
potenc
antibodi
viru
lectin
highli
potent
antihiv
activ
isol
differ
biolog
organ
gener
lectin
occur
larg
amount
natur
sourc
sourc
difficult
propag
thu
recombin
express
lectin
pursu
product
system
bacteria
yeast
later
system
lectin
product
optim
result
heterogen
product
nonfunct
product
product
form
insolubl
inclus
bodi
subsequ
lectin
produc
plant
gener
improv
outcom
respect
challeng
three
potent
antihiv
lectinsnam
cvn
grft
ahhav
express
tobacco
stabl
transgen
express
result
significantli
lower
level
accumul
product
rel
transient
product
lectin
highest
accumul
level
report
thu
far
lectin
produc
plant
grft
use
tmvbase
viral
vector
lectin
accumul
tobacco
leav
gkg
protein
ah
lectin
also
accumul
good
level
mgkg
use
icon
viral
vector
system
furthermor
plantproduc
lectin
review
seem
retain
nativ
efficaci
viru
subcellular
target
import
aspect
consid
produc
lectin
plant
sinc
lectin
express
may
affect
plant
process
yield
viabil
plant
cell
lectin
review
either
produc
secret
cytosol
protein
clear
compart
suit
lectin
sinc
high
level
cytosol
grft
secret
lectin
ah
report
thu
lectin
express
plant
system
might
produc
differ
cell
compart
evalu
optim
express
condit
lectin
apart
express
solitari
candid
microbicid
plant
also
abl
produc
fusion
lectin
antibodi
either
antibodylectin
fusion
entir
differ
molecul
administ
hiv
microbicid
like
consist
sever
compound
differ
mode
action
ensur
broad
maximum
activ
without
risk
develop
resist
produc
fusion
microbicid
one
combin
neutralis
potenti
two
molecul
singl
product
run
posit
implic
lower
cost
increas
efficaci
addit
fusion
stabilis
target
protein
ensur
higher
yield
exampl
elp
fuse
antihiv
antibodi
floss
et
al
clearli
product
microbicid
candid
molecul
offer
advantag
beyond
simpl
challeng
express
efficaci
molecul
twenti
year
research
plant
brink
enter
play
field
protein
product
platform
human
therapeut
progress
potenti
actual
product
platform
facilit
larg
technic
develop
vector
system
plant
host
diseas
hiv
desper
demand
effect
microbicid
advanc
could
potenti
enabl
plant
meet
suppli
gap
although
sever
antihiv
neutralis
antibodi
peptid
lectin
produc
plant
two
enter
clinic
trial
cocktail
sever
antibodi
produc
magnicon
system
n
benthamiana
whilst
plantmad
enter
clinic
trial
addit
plantproduc
grft
pass
preclin
studi
consid
safe
evalu
clinic
trial
advanc
plantmad
therapeut
clinic
develop
regulatori
approv
use
advanc
broad
access
trial
carrot
cell
glucocerebrosidas
provid
new
perspect
potenc
util
pmp
hope
product
purif
technolog
becom
standardis
field
plantmad
candid
progress
along
preclin
clinic
development
pipelin
plant
becom
sourc
routin
use
effect
therapeut
prevent
biolog
